Evidence map›Paper›PMID 38310334›Full record

ArticleInterdisciplinary cardiovascular and thoracic surgery2024

Plasma concentrations of histidine-rich glycoprotein in primary graft dysfunction after lung transplantation.

Toshio Shiotani, Seiichiro Sugimoto, Yasuaki Tomioka, Shin Tanaka, Toshiharu Mitsuhashi, Ken Suzawa, Kazuhiko Shien, Kentaroh Miyoshi, Hiromasa Yamamoto, Mikio Okazaki and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Interdisciplinary cardiovascular and thoracic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Toshio ShiotaniDepartment of General Thoracic Surgery and Organ Transplant Center, Okayama University Hospital, Okayama, Japan.
Seiichiro SugimotoDepartment of General Thoracic Surgery and Organ Transplant Center, Okayama University Hospital, Okayama, Japan.ORCID 0000-0001-6649-4777
Yasuaki TomiokaDepartment of General Thoracic Surgery and Organ Transplant Center, Okayama University Hospital, Okayama, Japan.
Shin TanakaDepartment of General Thoracic Surgery and Organ Transplant Center, Okayama University Hospital, Okayama, Japan.
Toshiharu MitsuhashiCenter for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
Ken SuzawaDepartment of General Thoracic Surgery and Organ Transplant Center, Okayama University Hospital, Okayama, Japan.ORCID 0000-0003-2463-9696
Kazuhiko ShienDepartment of General Thoracic Surgery and Organ Transplant Center, Okayama University Hospital, Okayama, Japan.
Kentaroh MiyoshiDepartment of General Thoracic Surgery and Organ Transplant Center, Okayama University Hospital, Okayama, Japan.
Hiromasa YamamotoDepartment of General Thoracic Surgery and Organ Transplant Center, Okayama University Hospital, Okayama, Japan.
Mikio OkazakiDepartment of General Thoracic Surgery and Organ Transplant Center, Okayama University Hospital, Okayama, Japan.
Shinichi ToyookaDepartment of General Thoracic Surgery and Organ Transplant Center, Okayama University Hospital, Okayama, Japan.ORCID 0000-0002-7588-6745
Okayama University Hospital · JP

Funding

Grant-in-Aid for Scientific Research 20K17747Japan Society for the Promotion of Science
6 · The paper itself

Abstract

objectivesHistidine-rich glycoprotein has been reported as an anti-inflammatory glycoprotein that inhibits acute lung injury in mice with sepsis and as a prognostic biomarker in patients with sepsis. We investigated the relationship between plasma concentrations of histidine-rich glycoprotein and the risk of occurrence of primary graft dysfunction.

methodsAccording to the primary graft dysfunction grade at post-transplant 72 h, patients who underwent lung transplantation were divided into three groups: non-primary graft dysfunction group (grade 0-1), moderate primary graft dysfunction group (grade 2), and severe primary graft dysfunction group (grade 3). The plasma concentrations of histidine-rich glycoprotein measured daily during the first post-transplant 7 days were compared among the three groups. Appropriate cutoff values of the concentrations were set for survival analyses after lung transplantation.

resultsA total of 68 patients were included. The plasma histidine-rich glycoprotein concentration at post-transplant 72 h was significantly lower in the severe primary graft dysfunction group (n = 7) than in the other two groups [non-primary graft dysfunction group (n = 43), P = 0.042; moderate primary graft dysfunction group (n = 18), P = 0.040]. Patients with plasma histidine-rich glycoprotein concentration ≥34.4 µg/ml at post-transplant 72 h had significantly better chronic lung allograft dysfunction-free survival (P = 0.012) and overall survival (P = 0.037) than those with the concentration <34.4 µg/ml.

conclusionsPlasma histidine-rich glycoprotein concentrations at post-transplant 72 h might be associated with the risk of development of primary graft dysfunction.

Indexed as

Chronic lung allograft dysfunctionHistidine-rich glycoproteinLung transplantationOverall survivalPrimary graft dysfunction

Identifiers

PMID38310334
PMCPMC10871901
OpenAlexW4391517801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.